# Long-term Extension of GTX-102 in Angelman Syndrome

> **NCT06415344** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 255 (estimated)

## Conditions studied

- Angelman Syndrome

## Interventions

- **DRUG:** GTX-102

## Key facts

- **NCT ID:** NCT06415344
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-07-31
- **Primary completion:** 2029-02
- **Final completion:** 2029-02
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06415344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06415344, "Long-term Extension of GTX-102 in Angelman Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06415344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*